P
ATRA icon

Pitcairn’s Atara Biotherapeutics ATRA Stock Holding History

Pitcairn’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-775
Closed -$31.2K – 645
2023
Q2 		$31.2K Buy
+775
New +$43.8K ﹤0.01% 653

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pitcairn's ATRA Position: Q3 2023 in Review

Pitcairn sold out of Atara Biotherapeutics (ATRA) in Q3 2023, closing a stake of 775 shares — an estimated $31.2K sold.

Pitcairn first reported a position in ATRA in Q2 2023 and held it in 1 quarter. The position peaked at $31.2K in Q2 2023. 109 funds tracked by Wall St. Rank hold ATRA as of Q3 2023.

  • Pitcairn reported no remaining Atara Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Pitcairn sold 775 Atara Biotherapeutics shares in Q3 2023, an estimated $31.2K.
  • Pitcairn first reported a position in Atara Biotherapeutics in Q2 2023 and held it in 1 quarter.
  • Pitcairn's Atara Biotherapeutics position peaked at $31.2K in Q2 2023.
  • 109 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2023.

Based on Pitcairn's 13F filing for Q3 2023, filed 13 Nov 2023.